Background: The combination of lapatinib and oral vinorelbine for HER2 positive metastatic breast cancer (MBC) is convenient but with uncertain toxicity profiles. A Phase I/II study was designed to understand the tolerability and efficacy of this combination treatment. Method: Female MBC patients with HER2 positive were eligible. Lapatinib was given once daily and oral vinorelbine was given on Days 1 and 8 of a 21-day cycle. A 3 + 3 standard dose-escalation rule was applied in the Phase I study. The primary endpoint of the Phase II study was PFS. In the Phase II part, because no DLT was observed in the first 20 patients, vinorelbine dose-escalation was permitted if no significant toxicities after the first cycle was observed. Result: From June 2009 to February 2013, 46 patients were enrolled in Phase I (n = 15) and II (n = 31) studies. Median age was 52.8 (range 34.3-84.0); 28 (60.9%) patients were ER positive. In the Phase I study, two patients had DLTs (neutropenia (n = 2), diarrhea (n = 1)). The MTD was determined at lapatinib 1000 mg plus oral vinorelbine 50 mg/m 2 . In the Phase II study, 11 patients
Introduction
Breast cancer is one of the cancers with the highest incidences in women worldwide and in Taiwan, and among them about 20% of the patients are HER2-positive (1) (2) (3) . The treatment of HER2-positive metastatic breast cancer (MBC) has improved dramatically after the introduction of anti-HER2 agents, especially monoclonal antibodies trastuzumab and pertuzumab (4) (5) (6) . While taxanes plus trastuzumab with or without pertuzumab has been considered by many as up-front treatment for HER2-positive MBC, the side effects and inconvenience such as short-interval clinic visits and needleplacement for intravenous (IV) infusion may complicate the longterm compliance of these treatments.
Lapatinib is an oral epidermal growth factor receptor (EGFR)/ HER2 dual blockade small molecular agent that is efficacious for HER2-positive MBC (7) . Although lapatinib was originally approved for trastuzumab-resistant HER2-positive MBC patients, some studies had demonstrated treatment efficacy of lapatinib either in combination with chemotherapy (8, 9) or hormonal (10) setting as earlier line of treatment for HER2-positive MBC. The combination of lapatinib and capecitabine has been considered suitable for second-line or later treatment and a superior choice for patients with brain metastases, where large antibody is less penetrated because of the blood-brain barrier (8, 11) .
Vinorelbine has been shown that it is an efficacious agent in HER2-positive MBC in various clinical trials either as a single agent or in combination with a HER2-targeted treatment (12) (13) (14) (15) . Preclinical models even predicted that vinorelbine in combination with an anti-HER2 agent was more efficacious than the combination of taxanes and an anti-Her2 agent (16) . Vinorelbine also have the advantage that two forms-intravenous and oral forms-are available for clinical treatment. The oral form has been demonstrated to have acceptable bioavailability and similar toxicity profile as compared with the IV form (17) .
With the median overall survival (OS) of HER2-positive patients extended to over 4 years (6), how to schedule and sequence the available treatments to provide the optimal quality of life as well as maintaining compliance to treatments become ever more important. Oral combinations of both HER2-targeting and cytotoxic agents have the advantage of less frequent clinic visits, no need for needlepenetration for a Port-A catheter or intravenous line, and more likely to be alopecia-free. Although the combination of lapatinib and capecitabine have been established as a viable second-line treatment choice, the notorious hand-foot syndrome, paronychia and diarrhea still makes room for improvement in the choice of oral combinations.
In this study, we aimed to establish first the safety of the combination of lapatinib and oral vinorelbine, and observe the efficacy of the combination of lapatinib and oral vinorelbine at the maximum tolerated dose (MTD) as first-line treatment for HER2-positive MBC.
Patients enrollment and study design
Eligibility criteria HER2-positive metastatic breast cancer female patients, regardless of hormone receptor (HR) status, were eligible. HER2-positive was defined as a 3+ by immunohistochemical (IHC) stain or a 2+ IHC stain accompanied by ≥2.2 ratio of HER2/CEP17 or absolute HER2 copy number >6 by fluorescent in situ hybridization (FISH). Other noticeable inclusion criteria included: age ≥ 20, ECOG performance status 0-2, at least one measurable lesion, no active brain metastases, and normal cardiac function with a left ventricular ejection fraction (LVEF) >50%. For HR-positive patients, hormonal therapy was not allowed during study. This clinical trial was approved by the Research Ethical Committee of the participating institutions and is listed on Clinicaltrial.gov (NCT00912275).
Study design
Phase I study The Phase I study utilized a standard 3+3 design; five dose-escalation levels were planned (Table 1) . Lapatinib was given once daily and vinorelbine was given on Days 1 and 8 of a 21-day cycle. Each level would enroll at least three patients. If less than 33% of the patients experienced dose-limiting toxicity (DLT), following patients would be enrolled into the next level. The maximum tolerated dose (MTD) was defined as the dose that ≥2 out of 3 or ≥3 out of six patients develops a DLT during the first cycle. Adverse events were recorded according to CTCAE version 3.0. Intra-patient dose-escalation was allowed if higher dose levels were regarded safe. Patients in the Phase I study could have received prior anti-HER2 treatment or cytotoxic including vinorelbine treatments in metastatic setting.
Phase II study After MTD was determined, chemo-naïve HER2-positive MBC patients were enrolled. Trastuzumab treatment in the neoadjuvant or adjuvant setting is permitted provided that at least 12 months has elapsed since the last dose of trastuzumab therapy. The recommend dose for Phase II study was predetermined as one dose level lower than the MTD. The primary endpoint of the Phase II study was initially progression-free survival rate at 6 months but later amended to progression-free survival (PFS) to increase event numbers needed after poor accrual. Secondary endpoints included objective response rate (ORR), overall survival (OS), clinical benefit rate (CBR) and safety profile. Tumor assessment was based on RECIST 1.1. Clinical benefit rate was based on patients who had complete response (CR), partial response (PR) or a stable disease longer than 24 weeks.
Later in the Phase II study, because no DLT emerged from the first 20 patients who received recommended dose treatment (dose level II), we considered escalating vinorelbine dosage. After protocol amendment of Phase II part, the last 11 patients could have their dose escalated to dose level III if no major toxicities were noted during the first-cycle (dose level III: vinorelbine 60 mg/m 2 on D1, D8
and lapatinib 1000 mg per day) for subsequently enrolled patients who do not have DLT in the first cycle of recommended dose treatment. 
Statistical analysis
Although the primary endpoint was PFS, we applied a minimax Simon 2 stage plan of the efficacy analyses, in order to have a preplanned stopping rule if futility is inevitable. Patients in the Phase I study who received the MTD dose were included in the efficacy analyses as well. However, to fit the criteria of using binary endpoint instead of survival events in the original Simon 2 stage design (18), we used 6-month PFS rate as the endpoint to determine the adequate sample size. The combination of lapatinib and oral vinorelbine was considered worthy of further study if the proportion of progression disease is 50% or lower after 6 months of treatment, which was based on the previous study showing first-line trastuzumab and vinorelbine combination had a median time to treatment failure of 5.6 months (12). With type 1 and type 2 errors of 0.05 and 0.1, respectively, this design calls for 29 patients at the first stage. If 20 or more progression disease is observed after 6 months of treatment, then the study will be terminated. Otherwise, additional 25 patients would enter the second stage. The treatment would be rejected if a total of 37 or more progressions were observed out of 54 patients after 6 months of treatment. With the estimated dropout rate of 10%, 32 patients will be accrued in the first stage and 28 in the second stage. During the study period, due to slow accrual and financial considerations, the Sponsor terminated the enrollment. Before termination of the study, we have successfully crossed the first part of the Simon 2 stage design and started recruiting patients for the second part. In the end, we had 15 and 31 (29 part I, 2 part 2 of the Simon 2 stage design) patients enrolled into the Phase I and II studies, respectively. Forty patients were available for efficacy analyses.
For efficacy analyses, survivals were estimated using KaplanMeier method with 95% confidence intervals (CI) and tested using log-rank test. A P value < 0.05 was considered significant.
Results
From June 2009 to February 2013, 15 and 31 patients were enrolled in Phases I and II study, respectively. The median age was 52.8 (range 34.3-84.0) and the median follow-up time was 39.2 months (range 6.1-62.2). The median treatment cycles of Phases I and II patients was 4 (range 3-86) and 8 (range 3-61), respectively. Twenty-eight (60.9%) patients were ER positive. The demographics of Phases I and II patients are shown in Table 2 .
Safety profile
In the Phase I study, two out of three patients in dose level III (vinorelbine 60 mg/m 2 and lapatinib 1000 mg) had DLT. One patient had
Grade 3 diarrhea and Grade 3 neutropenia, and the other patient had a prolonged neutropenia delaying the cycle 2. No DLTs were noted from the six patients treated at level II (vinorelbine 50 mg/m 2 and lapatinib 1000 mg). Thus, dose level II was declared the recommended dose for Phase II. Other common (≥40%) Grade 1/2 adverse events occurred in cycle one included: diarrhea (80.0%), skin rash (66.7%), fatigue (60.0%) and nausea/vomiting (40.0%).
In Phase II study, 11 patients had their dose escalated to dose level III if no major toxicities were noted during the first-cycle. Eventually, 20 patients were treated with level II dose and 11 patients were treated with level II dose for 1 cycle and followed by level III dose thereafter (these patients will be referred to as level III patients in this manuscript afterwards). Grade 3/4 AEs in the firstcycle included neutropenia (12.9%), diarrhea (3.2%) and infection (3.2%). Common Grade 1/2 AEs were similar to the Phase I results.
Additional safety data were also collected for patients who had treatment for at least eight cycles. In Phase I and II studies, the rate of Grade 3/4 neutropenia was 13.3% (2/15) and 22.6% (7/31) per patient number, respectively. The risk of severe Grade 3/4 diarrhea was not increased in the first eight cycles of treatment, but any grade of diarrhea was reported in 96.8% (30/31) of the Phase II patients. The DLTs/Grade 3/4 and common Grade 1/2 AEs (≥40%) in firstcycle of Phase I and first eight cycles of Phase II are shown in Table 3 .
In the Phase II study, four subjects experienced Grade 1/2 neutropenia after eight cycles (12.9% per patient number). In these four subjects, only one subject had an episode of Grade 3 neutropenia on cycle 10. Intriguingly, this patient has had repeated Grade 3 neutropenia despite dose adjustment and G-CSF support in the first eight cycles.
Long-term cardiac safety
Routine cardiac ultrasonography was used to follow cardiac function. Seven (15.2%) patients in Phase I and II studies had heart function evaluation for longer than 36 weeks; the median baseline LEVF was 62.6% (range 53.0-77.0). The median LEVF at 36 weeks was 63.8% (range 57.5-68.5) in Phase I and 70.0% (range 66.0-82.0) in Phase II study, respectively. There was no decrease in measured LVEF.
Efficacy
In Phase II study, a total of 20 and 11 patients received level II (vinorelbine 50 mg/m 2 and lapatinib 1000 mg) and III (vinorelbine 60 mg/m 2 and lapatinib 1000 mg) dose, respectively. After a median follow-up of 34.0 (range 6.1-56.7) months, there were 26 and 10 events for PFS and OS, respectively. The median PFS was 5.6 months (95% confidence interval (CI) 5.19-5.92) and the median OS was not reached (Fig. 1) . In the combined analysis, additional nine patients in the Phase I study who received the MTD dose level or recommended dose level (level II and III) were included. Among a total of 40 patients, the median PFS was 5.5 months (95% CI 3.57-7.40) and the median OS was not reached. Six (19.4%) patients in Phase II study had PR, and CBR was 38.7%. A higher dose (level III vs. level II) of vinorelbine was not associated with a better disease control rate according to CBR (P = 0.66), PFS (P = 0.73) or OS (P = 0.11).
Combining the results from Phase I and II, long-term disease control (no disease progression for more than 2 years) was achieved by 13.0% (6/46) of patients, with two ER positive and four ER negative patients. Among patients who had disease progression records, 13.2% (5/38) had brain metastasis progression. When testing a drug combination, the drug interactions through the cytochrome P 450 (CYP) system is always an important consideration (19, 20) . For lapatinib and vinorelbine, both of them are considered to affect the CYP system. In the Phase II clinical trial of lapatinib in combination of paclitaxel, higher than expected rates of severe diarrhea was thought to result from the impairment of the metabolic CYP system (9) . In the BOLERO-3 study, in which everolimus was added to both trastuzumab and vinorelbine to overcome possibly drug resistance, only 5 mg (half the dose of recommend dose) of everolimus was given daily, which may also because of the effect of vinorelbine on the CYP system (21) . Due to the abovementioned reason, we started the combination of lapatinib and oral vinorelbine as a dose-escalation Phase I study and shifted to Phase II study after we had come up with a maximum tolerated dose. However, there is no DLT event noted in the first 20 patients enrolled in the Phase II study. Therefore, explored dose-escalation of the oral vinorelbine dose in patients who tolerated the recommended dose without significant toxicities. The results that no additional toxicities were seen suggested that this could be considered in clinical practice when using this combination to treat HER2-positive patients.
The adverse events that may persist when targeted agents or oral chemotherapy were given chronically were considered to be less well reported (22) . In this study, we reported long-term AEs throughout the eight courses of treatment and also cardiac function monitoring result. Neutropenia risk may slightly increase but other severe toxicities did not emerge. Cardiac function remained stable throughout the 2-year follow-up period. As compared with the combination of lapatinib and capecitabine, lapatinib plus vinorelbine may has a slightly higher rate of Grade 3/4 neutropenia (but not febrile neutropenia) but less severe diarrhea and hand-foot syndrome.
The Phase II part was conducted in the setting of trastuzumabnaïve metastatic HER2-positive MBC patients. Although either trastuzumab plus pertuzumab-based or trastuzumab-based chemotherapy combination (where pertuzumab is not available) are the general recommendations from many guidelines, the combination of lapatinib and oral vinorelbine still offers the advantage of needlepenetration free and less frequent clinic visits as compared with trastuzumab-based treatment. In addition, there are 13% (6/46) patients who could remain needle-free as well as alopecia-free because of lapatinib and vinorelbine treatment for as long as two years. The result is even more impressive when four out of the six patients with long-term response were ER-negative, a subtype that we thought was more aggressive as compared with ER-positive MBC patients. We are not advocating that lapatinib plus vinorelbine can replace the current HER2-antibody based first-line treatment, but this dual oral combination could be reserved for specific patient population that strongly desires for less needle and alopecia experience.
Brain metastases as the organ of treatment failure has been an important topic in the trastuzumab-era of HER2-positive MBC. However, the efficacy of lapatinib in preventing or asymptomatic brain metastatic tumors is more controversial. In CEREBEL, lapatinib plus capecitabine failed to demonstrate a superior effect in the prevention of brain metastases as compared with trastuzumab plus capecitabine; however, patients with asymptomatic brain metastases were excluded (23) . In the exploratory analysis of a Phase III randomized study comparing trastuzumab emtansine (T-DM1) and lapatinib plus capecitabine, central nervous system (CNS) progression was numerically lower in the lapatinib plus capecitabine arm as compared with T-DM1 for both those who were without brain metastasis at baseline (0.7% vs 2.0%) and with asymptomatic brain metastasis at baseline (16.0% vs 22.0%); however, T-DM1 conferred a better OS for patients with brain metastatic tumors at baseline (HR 0.38, P = 0.008) (24) . In our study, lapatinib may have exerted from efficacy in brain metastasis control, as only 13% of the patients (5/38) had brain metastases as part of the organ of treatment failure, which is considered numerically lower than the expected brain metastases failure rate of 20-30%. Nevertheless, the small sample size strongly limited this interpretation. It would be helpful to understand the optimal sequence or appropriate time to incorporate lapatinib-based treatment for control of brain metastasis in the era where multiple HER2-based treatments are available.
There are also other limitations to our study. First, the poor accrual most likely is the reflection of the general acceptance of HER2-antibody based regimen as first-line therapy for HER2-positive MBC. As we have previously mentioned, the dual oral combination is more reserved for specific HER2-positive MBC population who has specific demands regarding needle or alopecia experience. Secondly, the early termination of the study and thus small patient population also provided less power to clearly interpret the efficacy results. Patients should still be monitored closely for efficacy results when prescribed the dual oral combinations.
In conclusion, our Phase I/II clinical trial demonstrated that the oral combination of lapatinib and vinorelbine is safe with manageable toxicities with clinical benefit for HER2-positive MBC patients. Although the efficacy is clearly lower than trastuzumab-based chemotherapy regimens, long-term disease control were observed in a contain percentage of patients, without needle-penetration or alopecia is possible. This combination could be considered as an alternative choice for physicians in treating HER2-positive MBC patients. 
